A validated, reliable and accurate reversed-phase high performance liquid chromatographic method using pre-column derivatization was adopted for the simultaneous determination of two ternary mixtures containing omeprazole, tinidazole and doxycycline hyclate or clarithromycin. Separation was achieved on a C18 column, through a gradient elution system using acetonitrile -methanol-water adjusted to pH 5 6.60. Drugs were detected at 277 nm over concentration ranges of 1 -112, 5-125, 2.5 -550 and 2.5 -100 mg/mL for omeprazole, tinidazole, doxycycline hyclate and clarithromycin, respectively. This is the first method that has isolated and identified clarithromycin derivative by infrared and mass spectroscopy. This method is the first study for the simultaneous determination of omeprazole, tinidazole, doxycycline hyclate and clarithromycin in combined mixtures and pharmaceutical formulations.
Introduction
Helicobacter pylori colonization of the gastric mucosa is one of the most common chronic bacterial infections in humans and the most important etiopathogenic agents for gastric and duodenal ulcers (1) . Because of the resistance of this organism, multidrug therapy is required (2) . Triple therapies use proton pump inhibitors (PPI), primarily omeprazole (OME), combined with tinidazole (TNZ) and either doxycycline hyclate (DOX) or clarithromycin (CLA), which are all given twice a day for a one-week regimen, according to European recommendations, whereas guidelines from the United States recommend 10 or more days of therapy (3) . OME ( Figure 1A ), is one of the most widely prescribed PPIs, which act by blocking the enzyme system responsible for active transport of protons into the gastrointestinal lumen, namely the H þ /K þ ATPase of the gastric parietal cell, thereby inhibiting the production of gastric acid (4) . TNZ ( Figure 1B) , represents a class of drugs, namely anti-parasites, that are commonly used for the management of many protozoan infections caused by amoebae, giardia and trichomonas (4) . DOX is an antibacterial that belongs to the tetracycline series ( Figure 1C ). It was developed as a therapeutic agent for the treatment of chronic prostatitis, sinusitis, syphilis, chlamydia, pelvic inflammatory disease, acne, rosacea and rickettsial infections (4) . Finally, CLA is a semi-synthetic 14-membered macrolide antibiotic ( Figure 1D ) that shows good antimicrobial activity against a wide range of Gram-positive and Gram-negative organisms (4).
Throughout a comprehensive scientific literature review, the triple combination therapy of OME, TNZ and DOX or CLA, is not presented in United States Pharmacopeia (USP), European Pharmacopeia (EP) or British Pharmacopeia (BP) for routine quality control analysis. In this respect, an analytical method for such a combination is beneficially needed. Similarly, no analytical method has been reported for the simultaneous determination of OME, TNZ and DOX or CLA in a multi-component mixture, whereas many analytical methods have been developed for the quantitative analysis of these compounds, either alone or in combination with other drugs, in various pharmaceutical dosage forms and human biological fluids. Such methods have included high-performance liquid chromatography (HPLC) and other related chromatographic techniques (5-11), gas-liquid chromatography (GLC) (12) , thin-layer chromatography (TLC) and high-performance thin-layer chromatography (HPTLC) (13 -17) , flow injection analysis (18) , chemiluminescence (19) , capillary electrophoresis (20 -21) , polarography (22) , spectrofluorimetry (23) and spectrophotometry (24) .
Like all macrolides, CLA is found to be lacking a suitable chromophore, allowing it to possess only a weak ultraviolet (UV) absorbance in the low wavelength range (,220 nm), making it difficult to develop a specific, selective and sensitive method using conventional UV detection. Because chemical derivatization can increase detection sensitivity and improve selectivity by means of pre-column or post-column HPLC (25) , several HPLC methods using a pre-column derivatization technique have been reported for an improved assessment of CLA in biological matrixes; such methods include the use of 9-fluorenylmethyl chloroformate (FMOC-Cl) as a labeling agent with fluorescence detection (26, 27) , or the use of trimethylbromosilane (TMBS) as the derivatizing reagent with UV detection (28) .
The use of TMBS for CLA pre-column derivatization in this paper was favorable for providing a much cleaner procedure, shortened pre-treatment cycle and a more sensitive HPLC technique for the simultaneous determination of CLA with the weakly basic nitrogenous drugs, OME and TNZ. This method is far more cost-effective, because the UV detector is much less expensive than to HPLC-fluorescence detection.
The fundamental advantage of this study compared to the previously reported method (28) is that this study has isolated the derivatized CLA and characterized it by mass and infrared (IR) spectroscopy to either falsify or verify the postulated reaction mechanism in the previously reported method.
Experimental

Materials and reagents
All experiments were performed using pharmaceutical-grade authentic standards of OME or CLA (Sigma Pharmaceuticals, Kowesnna, Egypt), TNZ (Medical Union Pharmaceuticals, Abo-sultan, Egypt) and DOX (Adwia Pharmaceuticals, 10th Ramadan, Egypt), which were certified to contain 99.9, 99.6, 99.7 and 99.8% (w/w), respectively, on a dried basis.
Acetonitrile and methanol (SDS, France) were of HPLC grade. TMBS 97% (Alfa Aesar, Germany), dry dichloromethane (Alfa Aesar), potassium dihydrogen phosphate (winlab, UK), sodium hydroxide (Merck, India), triethylamine and orthophosphoric acid (Riedel-de Haen, Germany) used were of analytical grade. The water for HPLC was prepared by double-glass distillation and filtration through 0.45 mm cellulose nitrate membrane filters (Chemlab, Spain). All chemicals were used as received without further modification or purification.
The 0.03M phosphate buffer was prepared by dissolving 4.08 g of potassium dihydrogen phosphate in 1 L of distilled water for HPLC.
The studied pharmaceutical preparations Trio and Trioclar, manufactured by Alkan (6th October, Egypt), were purchased from a local drugstore. Each was declared to contain each drug in separate: 20 mg OME, 500 mg TNZ and 50 mg DOX for Trio, and 20 mg OME, 500 mg TNZ and 500 mg CLA for Trioclar; each drug is labeled in different capsules, in addition to the excipients.
Instrumentation and chromatographic conditions
The chromatographic analyses were performed via a Knauer HPLC system (Berlin, Germany). This HPLC system consists of a manually driven 20 mL loop injector, two 54103 Smartline pumps (model series 100) and a Smartline HP-variable ultraviolet-visible (UV-Vis) detector (model series 2500) equipped with a 14 mL flow cell. The detection wavelength was set at 277 nm, where the investigated compounds exhibit their local maxima, which was selected using a double-beam Shimadzu (Tokyo, Japan) UV-1601 PC UV-Vis spectrophotometer (10 mm optical path length, matched quartz cell). Chromatographic separation was achieved on a reversed-phase analytical Discovery C18 column (250 Â 4.6 mm, i.d., 5 mm p.s.) (Supelco, Bellefonte, PA). A Mul-tec 770 electronic balance (Multec, Troy, MI) was used for the weighing procedures.
The optimal composition of the mobile phase through a gradient elution mode was a binary mixture of methanol -0.03M potassium dihydrogen phosphate buffer -triethylamine (30:69.7:0.3, v/v/v), adjusted with 1 M orthophosphoric acid to a pH of 6.6 + 0.1 as mobile phase A and acetonitrile as mobile phase B. The elution was initially conducted isocratically for the first 6 min using 15% of mobile phase B with a flow rate of 1.5 mL/min for the separation of both TNZ and DOX, and then mobile phase B was gradient up to 30% over 1 min with a final flow rate of 2 mL/min. This composition and flow rate were maintained for an additional 2.5 min (9.5 min), allowing the detection of OME. Subsequently, the composition was altered gradually over another 1 min to 55% mobile phase B and held for 4.5 min (15 min), revealing the CLA derivative. Finally, the analytical column was reconditioned and both the initial eluent composition and flow rate were restored over a 3 min time gap. The mobile phase was pumped over an average operating pressure of 95.8 -119.3 MPa. The pH was adjusted by a Cole Parmer pH-meter, the mobile phase was filtered using a Phenomenex vacuum filtration system equipped with 0.45 mm nylon membrane filter (ChromTech, Canada) and finally degassed for 30 min via an ultrasonic bath. The column was flushed with methanol at 3 mL/min flow rate for 5 min before the analysis of each set of the four analytes and the mobile phase was allowed to run for 10 min before each analysis. All determinations were performed at ambient temperature (258C + 1). Samples were injected at 20 mL of injection volume using a 25 mL Hamilton analytical syringe.
The whole chromatographic system was driven by EuroChrom, version 3.05 chromatography manager software (Knauer, Germany), which was also used for acquisition and processing of the chromatograms. Statistical analyses were done using SPSS Statistics, version 17.0 (IBM, Armonk, NY).
Procedures
Preparation of standard solutions Stock standard solutions were prepared separately to give a final concentration of 500 mg/mL for OME, TNZ, DOX or CLA, through dissolving an accurately weighed amount (50 mg) in a total of 100 mL methanol for TNZ, DOX and CLA, whereas OME was dissolved in 20 mL methanol and few drops of 0.1 M sodium hydroxide, then completed to final volume with water. Dissolution was achieved with the help of ultrasonication for 5 min.
Derivatization procedure An aliquot portion of diluted standard solution of CLA (50 mg/ mL) was transferred to a clean, dry Schlenk flask (50 mL capacity), where it was dried under a stream of nitrogen (N 2 ) at room temperature. The residue was resolved with 6 mL of dry dichloromethane (DCM), followed by an addition of 0.5 mL TMBS, which was then kept at 08C for 10 min. After this, 2 mL of water was added and the mixture was vortexed for 1 min to terminate the reaction and inactivate any excess TMBS. The solution mixture was centrifuged for 5 min at 2,700 rpm using an Eppendorf AG centrifuge (Hamburg, Germany) and the water layer was discarded. The organic layer was dried under a stream of N 2 at room temperature. The final residue was reconstituted with 1 mL of mobile phase A, then 20 mL of the reconstituted solution was injected into the chromatographic system.
Preparation of calibration curve standards
Working solutions for the standard calibration graphs were prepared immediately before use by further dilutions of the stock solutions with methanol, to cover the concentration ranges of 1 -112, 5 -125, 2.5 -550 and 2.5 -100 mg/mL for OME, TNZ, DOX and CLA, respectively. Three replicate 20 mL injections for each drug concentration level (simultaneously prepared) were made and directly chromatographed under the specified chromatographic conditions cited previously, except for CLA, which was chromatographed after its derivatization. The peak area values of each standard solution were plotted as a function of their corresponding concentrations, and subsequently, the equations of the calibration lines were calculated and represented in Table I . Precautions for light-controlling were implied throughout the experimental study against any drug photo-alteration reactions, especially for OME solutions.
Preparation and assay of synthetic mixtures Eight synthetic mixtures were laboratory prepared by accurately transferring aliquot portions of each drug standard solution to a series of 10 mL capacity volumetric flasks and completing to the volume with the specified mobile phase A to obtain the final injected amount ratios represented in Tables II and III. For combined mixtures containing CLA, the previously described derivatization steps were first applied for the whole combined drug mixture before its own analysis. The first two synthetic mixtures for each drug combination were at ratios similar to the drugs nominal concentrations within their relative pharmaceutical preparations. The concentrations of each compound fall within the ranges of its own calibration matrix. All mixtures were chromatographed through the previously specified chromatographic parameters, and the concentrations of each drug were calculated from the corresponding regression equations (Table I) .
Preparation and assay of pharmaceutical formulations
The contents of 20 capsules of each drug were separately ground in a mortar to homogenous powder lots. A portion of each finely powdered drug lot (according to the label claims), equivalent to 20 mg OME, 500 mg TNZ and 50 mg DOX in Trio capsules or 500 mg CLA in Trioclar capsules, was accurately weighed and transferred to a 100 mL volumetric flask. Seventy milliliters of mobile phase A were added to the mixture, which was dissolved via ultrasonication for 30 min at ambient temperature (258C + 1) and diluted to completion with mobile phase A. The solutions were filtered through 0.45 mm nylon membrane filter discs (Millipore, Milford, MA) before use. Further dilution was performed using the mobile phase to suit the concentration domain covered by the calibration graphs. For Trioclar capsules, the previously described derivatization steps were first applied for the whole combined drug mixture before its own analysis, and then the previously described comprehensive analytical procedures were followed and the concentration of each compound was calculated. To test the 
where C is the concentration of the reference standard substance mg/mL and Y is the peak area. † At 95% confidence limit (P 0.05). content uniformity, the same steps were followed, using one capsule of each drug as a sample, except that the mixture was sonicated for 60 min.
Results and Discussion
Spectral features
The UV absorption spectra of OME, TNZ, DOX, CLA and CLA derivative, prepared in mobile phase A, were found in the region of 200-425 nm, as represented in Figure 2 . It is obvious that each drug strongly contributes to the overall absorption spectrum of the mixture, resulting in an extensive overlapping between the absorption spectra of the drugs. Thus, introducing an HPLC technique for the simultaneous analysis of OME, TNZ, DOX or CLA in ternary mixtures will be more favorable than applying any conventional, derivative or derivative ratio spectrophotometric methods, which are found to be hindered by the spectral interference throughout the wavelength range.
Identification of CLA derivative
Concerning the CLA derivative, the suggested mechanism of the derivatization reaction was confirmed by the mass spectrum of obtained product from this reaction ( Figure 3 ). The mass spectrum revealed the primary peak m/z ¼ 999, which is equivalent to the expected mass of the CLA derivative. When comparing the IR spectrum of CLA to that of its derivative (Figure 4) , it was found that the broad band at 3,468 cm 21 in the IR spectrum of CLA, corresponding to its alcoholic OH groups, is not present in the IR spectrum of CLA derivative indicating the substitution of four OH groups of CLA by bromine. The suggested derivatization reaction mechanism is described in Figure 5 .
Method development and optimization
The proposed method was employed for the simultaneous analysis of OME, TNZ, DOX and CLA. Owing to their sparingly water solubility, different hydrophobicity, widely ranged pKa (2.34-9.5) (29) and varied acid -base reactivity (OME, TNZ and CLA are mild bases and DOX is amphoteric), a reversedphase HPLC with mobile phases containing an ion pairing agent will be suitable for the separation of these three analytes. Chromatographic parameters such as detection wavelength, mobile phase composition and proportions, pH and flow rates, and types of reversed columns, were thoroughly studied and optimized to provide an excellent assessment performance.
One of the crucial problem during this method development was the choice of a suitable mobile phase pH.,OME decomposes rapidly after protonation (acid catalysis) and the molecule possesses a half-life of only 1.4 h at pH ¼ 5.1, increasing to 38.5 h at pH ¼ 7.4 (30, 31) , reaching its maximum stability at pH ¼ 11 without any significant difference from pH ¼ 9 (32) . Moreover, the potency of DOX is reduced in solutions with a pH below 2; in addition, DOX undergoes reversible epimerization in solutions into the less active 4-epitetracycline, which is the most dominant degradation reaction at pH ¼ 2.5 to 5 (33) . This indicates a preferable use of basic media for OME and DOX. However, an analysis above pH ¼ 7 was to be avoided for three reasons; first, a mobile phase pH . 7 could damage the silica-based analytical columns, either cyano-propyl or octyl and octadecyl, when they are used frequently. Also, DOX exhibited severe peak tailing and band-broadening due to its increased hydrophobicity; consequently, it will interact more with the hydrophobic stationary phase, resulting in poor resolution with TNZ. Similarly, the retention times of both the basic lipophilic CLA and its more lipophilic derivatized form were prolonged with increasing pH. This is why, at apparent Figure 2 . UV absorption spectra of 20 mg/mL OME (a), 50 mg/mL TNZ (b), 50 mg/mL DOX (c), 50 mg/mL CLA (d) and 50 mg/mL CLA derivative (e) in mobile phase A. pH ¼ 6 -7, good baseline separation was achieved during the experimental study for TNZ and DOX with a conserved OME uniformity (stability) up to 24 h. The pH was then optimized at 6.6, favoring the use of a C18 analytical column over the cyanopropyl column; this avoided the drawbacks of repeatable working near the extreme tolerable pH for the cyan-propyl column, which could shorten its lifespan. However, the chosen pH (6.6) still allows low ionization and prolonged retention for the CLA derivative. That crucial problem was a second analytical challenge that was circumvented throughout the optimization of the mobile phase composition and flow rate. After several preliminary investigatory chromatographic runs, it was concluded that phosphate buffers gave better peak symmetry than their acetate and citrate counterparts. It was also noticed that peak shapes were improved with increasing the buffer ionic strength (0.01, 0.03, 0.05 and 0.06 M). However, to avoid salt precipitation that can affect the life span of the column, a 0.03M phosphate buffer was chosen for method validation. An initial mixture of methanol and phosphate buffer was tried in the ratio of 20:80 (v/v). Unfortunately, severe DOX peak tailing (.2) with OME and CLA derivative delayed elution that reached a retention times (t R ) . 17 min and . 60 min, respectively. When methanol was replaced with acetonitrile at the same ratio, better separation was obtained, but with relative tailing for the OME peak (tailing factor . 1.8).
Increasing the acetonitrile concentration to more than 60% led to inadequate separation of TNZ and DOX. Therefore, methanol was again introduced, and through a series of screening trials, a satisfactory separation of the three drugs was achieved by a mobile phase consisting of acetonitrile -methanol -0.03 M potassium dihydrogen phosphate buffer, pH ¼ 6.6, in a final ratio of 15:25:60 (v/v/v). The addition of 0.03 mL/L triethylamine (as ion-pair reagent) was beneficial to prevent tailing and band-broadening, and to reduce the retention times for OME and especially DOX peaks, because this antibiotic forms chelate complexes with divalent and trivalent cations including aluminum and calcium, which are present in the surfaces of silica gel particles employed in the packing of more chromatographic columns. Moreover, it also strongly interacts with the free charge silanol groups located in the usually employed stationary phases and reversed phases (67).
However, at this isocratic elution, the CLA derivative still possessed a delayed elution drawback (t R . 30 min), which required the change to a gradient elution to minimize any detector response variation with the mobile phase composition, the gradient program was optimized to allow each quantified drug to be eluted in an isocratic condition. With such gradient elution (i.e., one step gradient elution), each compound was eluted on a defined plateau with constant mobile phase composition. Initially, the composition of the mobile phase through a gradient elution mode was a binary mixture of 0.03M potassium dihydrogen phosphate buffer (containing 0.3% triethylamine, adjusted by 1 M orthophosphoric acid to a pH of 6.6 + 0.1) as mobile phase A and acetonitrile -methanol (38:62, v/v) as mobile phase B. However, this composition failed to elute the CLA derivative before 20 min. For that, the optimal composition of the mobile phase was settled at a binary mixture of methanol -0.03 M potassium dihydrogen phosphate buffer -triethylamine (30:69.7:0.3, v/v/v), adjusted by 1 M orthophosphoric acid to a pH of 6.6 + 0.1 as mobile phase A and acetonitrile as mobile phase B.
The flow rate was initially set at 2 mL/min, causing TNZ to be eluted too rapidly at 1.66 min, which was almost at the solvent side. Therefore, the flow rate was gradually reduced until it was finally adjusted at 1.5 mL/min to separate TNZ at a reasonable time of 3.44 min away from the solvent peak. However, this flow rate (1.5 mL/min) allowed the CLA derivative to elute beyond 15 min, so in return, the combination of both flow-rate gradient and an elution gradient programming, also known as dual-mode gradient, was adopted to handle a reasonable retention time for the CLA derivative (t R ¼ 13.07 min). The final gradient elution program is described in Table IV .
Finally, the detection wavelength was set regarding the UV absorption spectra of the drugs (Figure 2 ) and their relative concentrations within the pharmaceutical formulations. Whereas TNZ is nominally 10 and 25 times more concentrated than DOX and OME, respectively, both drugs have strong contributions in the overall UV region (200 -425 nm). This is why an optimum detection wavelength was set at 277 nm during the chromatographic separation, favoring the quantification of both DOX and OME, which represent the less concentrated components of this ternary mixture. In addition, this chosen detection wavelength can greatly improve the sensitivity of the proposed method for the CLA derivative determination because of the high molar absorptive coefficient of the derivate, because it exhibits two absorption maxima (at 206 and 275 nm ).
The specificity of this HPLC method is illustrated by the typical chromatograms in Figure 6A -C, in which complete separation of the drugs was noticed. The average retention time + standard deviation of OME, TNZ, DOX and CLA derivative were found to be 7.94 + 0.0289, 3.34 + 0.0193, 5.05 + 0.0098 and 13.07 + 0.0294 min, respectively, for nine replicates. The obtained peaks were sharp and had clear baseline separation.
Method validation
Linearity and range (calibration curve)
The linearity of this proposed HPLC method was assessed by least-squares linear regression analysis of the calibration curve. According to the International Conference on Harmonization (ICH) guidelines, at least five concentrations must be used. In this presented study, six to eight different concentrations of each studied drug were chosen and prepared as previously discussed. Each concentration was injected in triplicate and the Figure 6 . Typical HPLC chromatograms using the dual-mode gradient system for 20 mL injections of: synthetic standard mixture sample (50 mg/mL for TNZ, 50 mg/ mL for DOX, 20 mg/mL for OME and 50 mg/mL for derivatized CLA) (A); extracted Trio capsule sample (B); extracted Trioclar capsule sample (C); extracted placebo sample containing tablet excipients (D). Peaks: TNZ (1); DOX (2); OME (3); derivatized CLA (4).
mean value of the peak area was determined for the calibration curve construction. The repeated runs were genuine repeats and not just repetitions at the same reading; this provided information on the variations of the peak area between samples of the same concentration. The regression analysis revealed a satisfactory correlation (r 2 ¼ 0.9991 -0.9999) and an intercept value not statistically (P 0.05) different from zero, thus indicating a good linearity of the calibration graphs and an excellent obedience of the system to Beer's law. Characteristic parameters for the regression equations of the HPLC method obtained by least-squares treatment of the results are given in Table I .
Detection and quantitation limits (sensitivity)
The limit of detection (LOD) for a HPLC method is the lowest analyte concentration that produces a response detectable above the noise level of the system, typically taken as three times the baseline noise. The limit of quantitation (LOQ) is the lowest level of an analyte that can be accurately measured, which is often evaluated as ten times the noise level. Both LOD and LOQ must be determined only for impurity methods, and are not a requirement for drug assay. Because the presented HPLC method is for the assay of OME, TNZ, DOX and CLA in pharmaceutical formulations, LOD and LOQ are not required (34) . However, it is always useful to demonstrate that the analyses are being conducted in a region that is above the LOQ values. Both quantities were calculated according to the equations of Miller and Miller (35) , where LOD ¼ (3.3 Â response signal standard deviation)/calibration slope and LOQ ¼ (10 Â response signal standard deviation)/calibration slope. The theoretical values were assessed practically and are shown in Table II . The LOQ data generally fall outside the optimum linear ranges for every analyte. However, as mentioned previously, these ranges should be regarded as limiting optimum values instead of absolute ones. Thus, analytes at concentrations higher than the LOQ values can be confidently determined without risks from the calibration graph. In addition, verification of the proposed LOD values was successfully achieved through visual inspection of chromatograms of the analyte solutions containing their calculated LOD concentrations.
System suitability System suitability tests were performed in accordance with the BP guidelines (36) , to ensure adequate performance of both the chromatographic system and the equipment for the analysis to be performed. The repeatability test was conducted by injecting six replicates of OME, TNZ, DOX and CLA derivative at concentrations 48, 60, 300 and 50 mg/mL, respectively. The observed percentage relative standard deviation (RSD) of peak areas for these repetitive injections were considered satisfactory, meeting the BP recommendation (RSD , 1.0). Other chromatographic parameters were calculated from experimental data, such as capacity factor (k') [also known as mass distribution ratio (D m )], relative retention (r), tailing factor (T f ) [also known as peak asymmetry factor (A s )], selectivity factor (a), resolution factor (R s ), apparent number of theoretical plates (N) and the height equivalent to a theoretical plate (HETP), all of which are usually employed in assessing the performance of the column. Results obtained from system suitability are presented in Table V . Good agreement was found when results were compared with the recommended values.
Precision
The precision of the proposed HPLC analysis was evaluated at repeatability and intermediate precision (reproducibility) levels by using three independent concentrations for each drug. The repeatability (intra-day precision) was determined within the same day, while the intermediate precision (inter-day precision) was assessed through three consecutive days. Every sample was injected in triplicate and both retention times (t R ) and peak areas were calculated. Within the examined time range, the peak area results presented in Table VI show excellent precision for the method both during one analytical run and between different runs, with an intra-day and inter-day RSD range of 0.05 -0.87 and 0.11-1.14%, respectively. Moreover, the RSD of the retention time was found to be less than 0.8 and 1.7% for intra-day and inter-day precision, respectively.
Accuracy (recovery)
The accuracy of the proposed method, which is defined as the nearness of the true values to the found values, was evaluated by measuring the drug recoveries by the standard addition technique and in synthetic mixtures. The standard addition analysis involves the addition of five concentration levels of each analyte standard solution (covering the linearity range and higher than LOQ) to pre-analyzed pharmaceutical tablet samples, containing 8, 50, 10 or 50 mg/mL of OME, DOX, TNZ or CLA, respectively. The resulting mixtures were extracted, derivatized (only for CLA) and analyzed by using the proposed method. Each set of addition was repeated three times, and the results were compared to those expected from the calibration curve. The percent recovery was calculated from the following equation:
where C t is the total concentration of the analyte found, C u is the concentration of the analyte present in the tablet formulation, and C a is the concentration of the pure analyte added to the tablet formulation. As shown in Table VII , the mean recoveries of the compounds were close to unity (98.92-101.01%), with RSD values ranging from 0.05 to 1.28%. The excellent recoveries of the standard addition method (Table VII) and laboratory prepared mixtures (Tables II and III) , suggest the good accuracy of the proposed method. Consequently, the excipients in the pharmaceutical formulation did not interfere positively or negatively in the analysis of these compounds in the pharmaceutical formulation.
Robustness
Robustness relates to the capacity of the method to remain unaffected by small but deliberate variations introduced into the critical method parameters. Four chromatographic parameters (factors), such as buffer pH, organic composition of the mobile phase, elution flow rate and columns from different manufacturers, were varied around the value set in the proposed method to reflect changes likely to arise in different testing environments.
The pH was varied in the range 6.4-6.8; the mobile phase organic strength was varied though a +0.3% (v/v) alteration of acetonitrile proportions over the gradient elution. The influence of the flow rate was evaluated between 1.45-1.5 and 1.95 -2.05 mL/min. Only one factor was changed at a time and the analyses were performed in replicate injections (n ¼ 3). The results, presented in Table VIII , confirm the robustness of the method, because the observed variations were less than 1.4 + 0.03%. Furthermore, the results obtained from the two different brands of the reversed stationary phases indicated no significant difference between the results from the two columns. Less variability in the retention times was also observed.
Ruggedness
The ruggedness of the method is assessed by comparison of the intra-day and inter-day assay results for OME, TNZ, DOX and CLA derivatives that were performed by two different analysts. The RSD values for intra-day and inter-day assays of OME, TNZ, DOX or CLA derivatives in the combined pharmaceutical formulation, performed in the same laboratory by two different analysts, did not exceed 3.5%, indicating the ruggedness of the proposed method.
Selectivity
The selectivity of the current method was demonstrated through different aspects. First, eight synthetic ternary mixtures of the studied compounds were laboratory prepared, as previously discussed. Satisfactory recoveries with small percentage RSD were obtained (Tables II and III) , indicating the high selectivity of the proposed method for simultaneous determination of OME, TNZ, DOX or CLA in their mixtures.
Second, an injection of a methanolic placebo solution, prepared by mixing the commonly used tablet matrix components (lactose, starch, magnesium stearate, talc, sodium lauryl sulfate, microcrystalline cellulose and hydroxypropyl cellulose), confirmed that the commonly used tablet excipients did not interfere with the four examined analytes, because they have no absorbance at 277 nm ( Figure 6D ). This was also confirmed by the accuracy assay. Finally, both the chromatograms and the spectra of each analyte (200 -425 nm) in the tablet sample solutions were identical to those received by the standard solution.
Stability of analytical solutions
Standard and sample analytical solutions of each studied drug in mobile phase A were evaluated for short-term and long-term stability. The solutions were stored in tightly capped volumetric flasks under reduced light conditions (wrapped with aluminum foil and in darkness). The solutions were kept inside the laboratory bench closet at room temperature ( 258C) for 12 h (shortterm stability), and for three days when stored under refrigeration at 4 + 28C (long-term stability). Recoveries of these solutions were periodically checked against freshly prepared solutions. The solutions exhibited neither absorbance nor chromatographic changes, and the percentage mean found concentration was within the acceptable limit (90-110%), indicating good stability.
Analysis of the pharmaceutical formulations
The validated HPLC method was applied for the simultaneous determination of OME, TNZ, DOX or CLA in combined pharmaceutical mixtures using Trio and Trioclar capsules. Five replicate determinations were performed at each concentration level on a two-day design. As illustrated in Table IX, results were expressed as the percentage of drug recovery related to the label claims, which were satisfactory with regard to the USP requirements of 90-110% of the corresponding label claims. Statistical comparison between the results using Student's t-test and the one-way analysis of variance (ANOVA test) with those obtained by the reported methods (11, 36 -38) was done. Both the t-test values and the variance ratio F-values obtained at the 95% confidence level did not exceed the theoretical tabulated values. Therefore, there is no significant difference between the proposed and reported methods, indicating that the proposed method is as accurate and precise as the reported methods.
Conclusion
A straightforward, simple, reliable HPLC method has been established for the simultaneous determination of OME, TNZ and DOX or CLA in combined synthetic mixtures and pharmaceutical formulations (tablets). The method validation was performed as per ICH guidelines. The method provides the advantages of large sample capacity and specific, efficient and clean procedure of the pharmaceutical formulation; there is no need for complex sample preparations, such as the extraction of the active constituents. Moreover, this is the first study that is intended to verify the postulated derivatization reaction mechanism of clarithromycin, which is conducted by identification of the CLA derivative by IR and mass spectroscopy. 
